KSD-101 treatment for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new therapy called KSD-101 for people with a type of nasopharyngeal cancer linked to the Epstein-Barr virus (EBV). It is for patients whose cancer has returned or spread and who have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old.
- You must have nasopharyngeal cancer that is positive for the Epstein-Barr virus (EBV).
- Your cancer must have come back in the same area, spread to other parts of the body, or be unable to be treated with standard approaches.
- You must be able to have a blood draw and have at least one tumor that can be measured on scans.
- You must be in generally good health, with adequate blood counts, liver, kidney, and heart function.
- You must not have had cancer treatment in the last 4 weeks or have other serious infections or medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This trial tests adding donor natural killer (NK) cells to standard chemoradiation for advanced nasopharyngeal cancer. It aims to see if this combination helps control the cancer better.
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
This trial tests a new treatment called KSD-101 for nasopharyngeal cancer that is linked to the Epstein-Barr virus (EBV) and has not responded to standard therapies. It aims to see if KSD-101 can help people whose cancer has come back or spread.
This early-stage trial tests KSD-101, a new cell therapy, in patients with EBV-related lymphomas (blood cancers) that have come back or stopped responding to previous treatment. The goal is to see if this treatment can help patients who have limited other options.
This trial tests KSD-101, a vaccine designed to help treat or prevent recurrence of blood cancers caused by EBV (Epstein-Barr virus). It may be used for patients whose cancer hasn't responded to standard treatment or as a preventive therapy after treatment.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.